rotigotine sustained-release / Auritec Pharma - LARVOL DELTA

Repurposing Approved Drugs Riluzole, Rotigotine, and Levetiracetam for Potential Treatment of Alzheimer Disease (Practical Neurology) - "Howard Fillit, MD...noted, 'Commercialization is critically important because if there is no commercial pathway, people are essentially unable to access the treatment. This is, in part, because without an indication from the FDA, no marketing can be done, making widespread dissemination of information about the new indication challenging. Additionally, without an indication, clinicians are put in a position of prescribing off-label, which has become much more difficult to do in the days of Medicare Part D and prior authorization.'"

Media quote • Alzheimer's Disease

The Effect of Rotigotine Extended-Release Microspheres Alone or With Celecoxib on the Inflammatory Pain. (PubMed, Front Pharmacol) - "Clinical trials of rotigotine extended-release microspheres (RTGT-MS), which provides a sustained release of rotigotine for near 2 weeks in vivo, have been conducted in the treatment of Parkinson's disease (PD)...Chlorpromazine, a dopamine receptor blocker, not only weakened the analgesic effect of RTGT-MS, but also increased the levels of cAMP, PKA, COX-2, and PGE2. These findings provide a rationale for the combination of RTGT-MS and celecoxib in the treatment of PD, which may reduce the dose of celecoxib, thereby lowering the incidence of adverse effects and improving the pain management in PD patients."

Journal • CNS Disorders • Movement Disorders • Pain • Parkinson's Disease